RYR1 and Malignant hyperthermia: The type 1 ryanodine receptor (RyR1) is a promising candidate as a target for inhaled anesthetics because mutations of RyR1 are linked to malignant hyperthermia (MH), a potentially life-threatening pharmacological disorder induced by the use of inhaled anesthetics [22,23].